Supernus Pharmaceuticals, Inc.
SUPN
$50.21
$0.300.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.11M | -45.12M | 22.50M | -11.83M | 15.33M |
| Total Depreciation and Amortization | 25.02M | 24.81M | 21.36M | 20.38M | 18.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.31M | 7.85M | 3.19M | 8.14M | 15.36M |
| Change in Net Operating Assets | -51.36M | -49.20M | 11.49M | 13.91M | -5.13M |
| Cash from Operations | 19.86M | -61.66M | 58.54M | 30.60M | 44.41M |
| Capital Expenditure | -427.00K | -129.00K | -455.00K | -327.00K | -213.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -293.09M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.88M | 341.93M | -30.15M | 37.64M | -12.43M |
| Cash from Investing | -51.31M | 48.71M | -30.61M | 37.32M | -12.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.56M | 23.74M | 3.28M | 2.04M | 6.88M |
| Repurchase of Common Stock | -31.00K | -811.00K | -46.00K | -3.34M | -987.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.86M | -2.30M | -20.10M | -- |
| Cash from Financing | 8.53M | 21.07M | 935.00K | -21.40M | 5.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.92M | 8.11M | 28.86M | 46.52M | 37.66M |